Table 4 Summary of Survival Data for Effective Agents in the Tsc2-/- Subcutaneous Tumor Model
Reference | Start Criteria | Treatment Cohort | Dosing | Median Survival (days) | Percent Difference From Untreated | Drug class |
|---|---|---|---|---|---|---|
Current Study | Tumor Volume of 100 mm3 | Untreated | - | 31 | - | Â |
| Â | Â | Rapamycin | 8 mg/kg 3 days/wk | 84.5 | 173% | * |
|  |  | Asparaginase | 2IU/g twice/wk × 4 wks | 39.5 | 27% | # |
|  |  | Asparaginase + Rapamycin | 2IU/g twice/wk × 4 wks + 8 mg/kg 3 days/wk | 71 | 129% |  |
| Â | Â | Sunitinib | 80 mg/kg 5 days/wk | 39 | 26% | # |
| Â | Â | Sunitinib + Rapamycin | 80 mg/kg 5 days/wk + 8 mg/kg 3 days/wk | 80 | 158% | Â |
| Â | Â | Bevacizumab | 5 mg/kg once/2 wks | 38.5 | 24% | # |
| Â | Â | Bevacizumab + Rapamycin | 5 mg/kg once/2 wks + 8 mg/kg 3 days/wk | 60 | 94% | Â |
Lee et al, 2009 | Tumor Volume of 150 mm3 | Untreated | - | 24.5 | - | Â |
| Â | Â | Rapamycin | 8 mg/kg 5 days/wk | 46 | 88% | * |
| Â | Â | Sorafenib | 60 mg/kg 5 days/wk | 19.5 | -20% | Â |
| Â | Â | Sorafenib + Rapamycin | 60 mg/kg 5 days/wk + 8 mg/kg 5 days/wk | 53 | 116% | ** |
Messina et al, 2007 | Tumor Volume of 50 mm3 for early treatments, 250 mm3 for late treatments | Untreated | - | 31 | - | Â |
| Â | Â | Early CCI-779 | 8 mg/kg 5 days/wk | 47 | 52% | * |
| Â | Â | Early Rapamycin | 8 mg/kg 5 days/wk | 62 | 100% | * |
| Â | Â | Late Rapamycin | 8 mg/kg 5 days/wk | 59 | 90% | * |
Lee et al, 2006 | Tumor Volume of 300 mm3 | Untreated | - | 17.5 | - | Â |
| Â | Â | CCI-779 | 8 mg/kg 5 days/wk | 41 | 134% | * |
|  |  | IFN-γ | 20,000 units 3 days/wk | 22 | 26% | # |
|  |  | IFN-γ + CCI-779 | 20,000 units 3 days/wk + 8 mg/kg 5 days/wk | 56 | 220% | ** |
Lee et al, 2005 | 18 Days after injection with Tsc2-/- cells | Untreated | - | 33 | - | Â |
| Â | Â | CCI-779 | 4 mg/kg 3 days/wk | 69 | 109% | * |
|  |  | IFN-γ | 20,000 units 3 days/wk | 50 | 52% | # |